Securities: Pump and Dump alert

LADIES AND GENTLEMEN:

Do you hear that????? OPPORTUNITY is KNOCKING AT YOUR DOOR. ACT NOW and ride the CASCADE all the way to the bank. The revolution begins with CASCADE TECHNOLOGIES, symbol "CSDT"� and it is just starting to heat up. This technology will revolutionize the diagnosis of cancer and precancerous conditions in a less evasive and less expensive manner. Cascade is an opportunity that is rarely seen with a stock price under a buck. GET IN NOW and ride the CASCADE of profits.

CASCADE (CSDT) has everything you should be looking for in an invstment, REVOLUTIONARY technology, STELLAR Product Commercialization, ROBUST intellectual property, LARGE UNTAPPED market, management with a PROVEN track record and WELL FUNDED AND STRUCTURED.

REVOLUTIONARY TECHNOLOGY. Optical Molecular Imaging ("OMI"�) was originally developed for satellite reconnaissance. The Company develops non-invasive devices that use OMI's patented technology for improved clinical diagnosis, primarily in the field of cancer, based on high resolution imaging, identification, and analysis of certain molecular, cellular, and tissue features via spectral imaging approaches.

The commercialization of this technology will significantly improve long-term patient outcomes while substantially reducing overall costs for the healthcare system and assists in the diagnosis and treatment of various diseases by:

- More reliable and quantitative in vivo/intrasurgical measurement of cellular features
- Early detection of both malignant and pre-malignant tissue
- Reduction in the number of invasive biopsy procedures
- Better monitoring and quantitation of treatments

STELLAR PRODUCT COMMERCIALIZATION. CASCADE intends to develop three products over the next four to five years: the MelaSpect device, the EndoSpect device, and the OxySpect device.
-

The MelaSpect device addresses the massive need for early, reliable, non-invasive diagnosis of and screening for skin cancer by advanced spectral imaging.

-

The EndoSpect device is a spectral/hyperspectral imaging endoscope that provides a more accurate way of investigating tissue status during gastro-intestinal and pulmonary endoscopy and minimally invasive surgery. This product provides for the early detection and diagnosis of cancer and pre-cancerous conditions.

-

The OxySpect device is a product for mapping tissue oxygenation by spectral imaging in a broad range of organs, body locations, and during procedures to assist in assessing tissue health during and after surgical intervention.

ROBUST INTELLECTUAL PROPERTY. The patented technologies are licensed from the prestigious Carnegie Mellon University, which is affiliated with 16 Nobel Laureates, the University which founded artificial intelligence in 1955, developed robotic machines which cleaned up the nuclear accidents at Three Mile Island and Chernobyl, the University also has a lighter side as they are credited with creating silly putty and emotioncons J their alumni include John Nash Jr. who's story was documented in the film "A Beautiful Mind"� and pop icon Andy Warhol.

LARGE UNTAPPED MARKET. Two million mostly negative biopsies are performed annually to detect melanoma. The Endoscopic imaging market it approx $4.3 billion per year solely for GI and lung applications in the U.S. alone. With the Company's high profit margins if the new products capture just a small portion of the market it will make the current eight million dollar market cap look ridiculous.

PROVEN MANAGEMENT. Dr. Daniel L. Farkas PhD, the former Director of the Center for Light Microscope Imaging and Biotechnology at the aforementioned Carnegie Mellon University. Dr. Farkas founded or co-founded a number of high-tech start ups, including ChromoDynamics, Inc., (acquired by Gooch and Housego PLC), TissueInformatics, Inc (acquired by Clinical Data, Inc) and ProteoRubix, Inc., and PhotoNanoscopy Inc.

WELL FUNDED AND STRUCTURED. According the Company's 8K filed on March 15, 2010 they have raised 1.15 million dollars in a private placement in addition Management has cancelled over 143 mill shrs leaving a little over 52 mill out, it is that type of quality management decisions that allows for cascades of profit for investors.

This is YOUR OPPORTUNITY to invest in Dr. Farkas current high tech start up on the ground floor, revolutionary technologies developed at the University that brought the world everything from artificial intelligence, robotic machines that cleaned up nuclear accidents to emotioncons and silly putty. How would have liked to invest in any of those products at these prices????This is a product that when commercialized will be less expensive and less invasive in a $4.3 billion dollar market, do the math even if they capture 1% of the market that's $43 mill in sales with large margins no matter what valuation you use the eight mill dllr market cap is a joke even if you use two times sales this Company has the potential of this increasing tenfold turning a thousand dollar investment into ten thousand dollars. While potential does not guarantee profits all the elements of success are in place. DO NOT MISS THIS OPPORTUNITY HOP ON BOARD YOUR INTELLECTUAL SURFBOARD AND RIDE THE CASCADE
TO MARKET PROFITS.

Happy Trading

This message was sent from : LogicAds, PO Box 4668 #82130, New York, New York 10163-4668.